Floatz Rating
B62/100
Confidence
Indicative
Sponsor
University of Miami
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
61High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06902246CT.gov Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma | — | Withdrawn | — | — | — |
NCT07495579CT.gov Lenvatinib or Regorafenib for Advanced Hepatocellular Carcinoma After Immunotherapy (REVIVE) | — | Not Yet Recruiting | — | — | — |
NCT07514455CT.gov Regorafenib After Treatment Failure of First Line Immune Checkpoint Inhibitor Treatment in Advanced Hepatocellular Carcinoma Patients | — | Not Yet Recruiting | — | — | — |
NCT07514429CT.gov Regorafenib After Failure of Lenvatinib in Patients With Unresectable HCC: The RELEVANT-HCC Trial | — | Not Yet Recruiting | — | — | — |
NCT07392866CT.gov A Clinical Study of SH006 Injection in Combination Therapy Versus Regorafenib in the Treatment of Advanced Hepatocellular Carcinoma | — | Not Yet Recruiting | — | — | — |
NCT07328009CT.gov A Platform Trial for Personalized and Adaptive Therapies in Hepatocellular Carcinoma | — | Recruiting | — | — | — |
NCT07310173CT.gov Phase IIb Study of AST-3424 in Patients With AKR1C3-high Expressing Advanced Hepatocellular Carcinoma | — | Recruiting | — | — | — |
NCT07300488CT.gov Efficacy and Safety of Pracytarabine Versus Regorafenib in the Treatment of Patients With Hepatocellular Carcinoma | — | Active Not Recruiting | — | — | — |
NCT07115550CT.gov A Single-center, Single-arm, Phase II Clinical Study of Iparomlimab and Tuvonralimab Injection Combined With Regorafenib in the Treatment of Advanced Second-line or Above Hepatocellular Carcinoma | — | Not Yet Recruiting | — | — | — |
NCT07100392CT.gov Tauroursodeoxycholic Acid (TUDCA) Plus Camrelizumab and Regorafenib in Hepatocellular Carcinoma Previously Treated With Anti-PD1/PD-L1 and Bevacizumab | — | Recruiting | — | — | — |
Show 36 more trialsShow fewer
NCT07078305CT.gov Comparing the Combination of Trastuzumab and Regorafenib With Regorafenib Monotherapy for Advanced Hepatocellular Carcinoma After First-line Treatment | — | Not Yet Recruiting | — | — | — |
NCT06375317CT.gov HAIC Combined With PD-L1 Plus Regorafenib in the Treatment of Advanced Hepatocellular Carcinoma After Immunotherapy Failure | — | Not Yet Recruiting | — | — | — |
NCT06280105CT.gov A Trial of Cadonilimab Plus Regorafenib in Patients With Hepatocellular Carcinoma Who Failed Camrelizumab Combined With Apatinib | — | Recruiting | — | — | — |
NCT05962450CT.gov Adoptive Autologous iNKT Cells for the Treatment of Progressed Hepatocellular Carcinoma Continuing on PD-1 Inhibitor Therapy | — | Unknown | — | — | — |
NCT04777851CT.gov Regorafenib-pembrolizumab vs. TACE/TARE in Intermediate Stage HCC Beyond Up-to-7 | — | Terminated | — | — | — |
NCT05773105CT.gov A Study of Cadonilimab Combined With Regorafenib in Patients With Advanced HCC | — | Completed | — | — | — |
NCT05622136CT.gov Dose-escalation of Regorafenib in Advanced Hepatocellular Carcinoma | — | Active Not Recruiting | — | — | — |
NCT05194293CT.gov Regorafenib and Durvalumab for the Treatment of High-Risk Liver Cancer | — | Active Not Recruiting | — | — | — |
NCT05917431CT.gov Phase 2 Study of SBRT Plus Tislelizumab and Regorafenib in Unresectable or Oligometastatic HCC | — | Recruiting | — | — | — |
NCT05770882CT.gov Chidamide + Regorafenib in Hepatocellular Carcinoma (HCC) | — | Terminated | — | — | — |
NCT05557656CT.gov A Real World Study of Regogfinib in HCC | — | Unknown | — | — | — |
NCT05811481CT.gov Regorafenib Alone or in Combined With Transcatheter Arterial ChEmoembolization in Treatment of Advanced Hepatocellular Carcinoma After First Line Targeted Therapy | — | Unknown | — | — | — |
NCT05644379CT.gov A Study Evaluating Cadonilimab Injection in Combination With Regorafenib for the Advanced Hepatocellular Carcinoma | — | Active Not Recruiting | — | — | — |
NCT05155189CT.gov A Study to Evaluate Safety and Efficacy of Armored CAR-T Cell Injection C-CAR031 in Advanced Hepatocellular Carcinoma | — | Recruiting | — | — | — |
NCT05233358CT.gov HAIC Combined With Second-line "Target Immunity" for HCC With TACE Standard Treatment Low Response or Failure | — | Unknown | — | — | — |
NCT05717738CT.gov Combined TACE, TKI/Anti-VEGF and ICIs as Conversion Therapy for Advanced Hepatocellular Carcinoma | — | Recruiting | — | — | — |
NCT05134532CT.gov Regorafenib After Progression on Atezolizumab Plus Bevacizumab in Advanced HCC | — | Unknown | — | — | — |
NCT05048017CT.gov Regorafenib Combined With PD-1 Inhibitor Therapy for Second-line Treatment of Hepatocellular Carcinoma | — | Unknown | — | — | — |
NCT04985136CT.gov A Study of Camrelizumab Combined With Rivoceranib Mesylate Versus Investigator's Choice of Regimen in Treatment of Patients With Advanced Hepatocellular Carcinoma (HCC) | — | Terminated | — | — | — |
NCT05025592CT.gov cTACE or DEB-TACE+HAIC Combined With Regorafenib ± Anti-PD1 Antibody for uHCC | — | Unknown | — | — | — |
NCT04806243CT.gov Carelizumab Combined With Regorafenib in the Treatment of HCC（CARE-2020） | — | Unknown | — | — | — |
NCT04696055CT.gov Regorafenib Plus Pembrolizumab in Patients With Advanced or Spreading Liver Cancer Who Have Been Previously Treated With PD-1/PD-L1 Immune Checkpoint Inhibitors | — | Completed | — | — | — |
NCT04327700CT.gov Study Of Intrabucally Administered Electromagnetic Fields and Regorafenib | — | Terminated | — | — | — |
NCT04476329CT.gov Optimization for Regorafenib in HCC | — | Terminated | — | — | — |
NCT04718909CT.gov Regorafenib Plus Sintilimab vs. Regorafenib as the Second-line Treatment for HCC | — | Unknown | — | — | — |
NCT04183088CT.gov Regorafenib Plus Tislelizumab as First-line Systemic Therapy for Patients With Advanced Hepatocellular Carcinoma | — | Unknown | — | — | — |
NCT04310709CT.gov Combination of Regorafenib and Nivolumab in Unresectable Hepatocellular Carcinoma | — | Completed | — | — | — |
NCT05713994CT.gov Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular Carcinoma | — | Recruiting | — | — | — |
NCT04170556CT.gov Regorafenib Followed by Nivolumab in Patients With Hepatocellular Carcinoma (GOING) | — | Completed | — | — | — |
NCT07537985CT.gov Efficacy and Safety Comparison Between PD-1 Inhibitor Combined With Lenvatinib or With Regorafenib For UHCC After Failure of First-line Treatment | — | Completed | — | — | — |
NCT03899428CT.gov Immune Checkpoint Therapy vs Target Therapy in Reducing Serum HBsAg Levels in Patients With HBsAg+ Advanced Stage HCC | — | Recruiting | — | — | — |
NCT03644511CT.gov Use of Sorafenib and/or Regorafenib in Liver Cancer (Hepatocellular Carcinoma) Subsequent to Another Systemic First-line Treatment | — | Terminated | — | — | — |
NCT03347292CT.gov Regorafenib Plus Pembrolizumab in First Line Systemic Treatment of HCC | — | Completed | — | — | — |
NCT03475953CT.gov A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors | — | Unknown | — | — | — |
NCT01774344CT.gov Study of Regorafenib After Sorafenib in Patients With Hepatocellular Carcinoma | — | Completed | — | — | — |
NCT01003015CT.gov Safety Study of BAY73-4506 in Patients With Hepatocellular Carcinoma | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Hepatocellular Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Regorafenib (this asset) | University of Miami | P3 | B · 62 |
| Adefovir | Bukwang Pharmaceutical | P4 | BBB |
| Huaier Granule | Tongji Hospital | P4 | BBB |
| Fluorouracilum | Li Qiang | P4 | BBB |
| Oxaliplatin | Li Qiang | P4 | BBB |
| Theprubicin | RWTH Aachen University | P4 | BB |
| Adriamycin | VA Office of Research and Development | P4 | BB |
| nrt6003 | Second Affiliated Hospital of Guangzhou Medical University | P3 | BB |
| Epirubicin | Fudan University | P4 | BB |
+42 more in the Hepatocellular Carcinoma cohort
Other indications for Regorafenib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Gastrointestinal Stromal Tumor | — | P4 | BBB · 73 |
| Colorectal Neoplasm | — | P4 | BB · 71 |
| Colorectal Adenocarcinoma | — | P2 | BB · 67 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Regorafenib in Hepatocellular Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/regorafenib-hepatocellular-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →